Drugs / DKF-MA102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06490328 | May 2024 → May 2025 overdue | prostate cancer | Dongkook Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DKF-MA102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06490328 ↗ |